Your browser doesn't support javascript.
The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series.
Zeng, Hao; Wang, Dongfang; Nie, Jingmin; Liang, Haoyu; Gu, Jiang; Zhao, Anne; Xu, Lixin; Lang, Chunhui; Cui, Xiaoping; Guo, Xiaolan; Zhou, Changlong; Li, Haibo; Guo, Bin; Zhang, Jinyong; Wang, Qiang; Fang, Li; Liu, Wen; Huang, Yishan; Mao, Wei; Chen, Yaokai; Zou, Quanming.
  • Zeng H; National Engineering Research Center of Immunological, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy and Laboratory Medicine, Third Military Medical University, Chongqing, P.R. China.
  • Wang D; State Key Laboratory of Trauma, Burn and Combined Injury, Third Military Medical University, Chongqing, P.R. China.
  • Nie J; Institute of Blood Transfusion, Chongqing Blood Center, Chongqing, P.R. China.
  • Liang H; Chongqing Public Health Medical Central, Chongqing, P.R. China.
  • Gu J; Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control, Beijing, P.R. China.
  • Zhao A; National Engineering Research Center of Immunological, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy and Laboratory Medicine, Third Military Medical University, Chongqing, P.R. China.
  • Xu L; National Engineering Research Center of Immunological, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy and Laboratory Medicine, Third Military Medical University, Chongqing, P.R. China.
  • Lang C; Chongqing University Three Gorges Hospital & Chongqing Three Gorges Central Hospital, Chongqing, P.R. China.
  • Cui X; Chongqing University Three Gorges Hospital & Chongqing Three Gorges Central Hospital, Chongqing, P.R. China.
  • Guo X; Chongqing University Three Gorges Hospital & Chongqing Three Gorges Central Hospital, Chongqing, P.R. China.
  • Zhou C; Affiliated Hospital of North Sichuan Medical College, Nanchong, P.R. China.
  • Li H; Yongchuan Hospital of Chongqing Medical University, Chongqing, P.R. China.
  • Guo B; National Engineering Research Center of Immunological, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy and Laboratory Medicine, Third Military Medical University, Chongqing, P.R. China.
  • Zhang J; Affiliated Hospital of North Sichuan Medical College, Nanchong, P.R. China.
  • Wang Q; National Engineering Research Center of Immunological, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy and Laboratory Medicine, Third Military Medical University, Chongqing, P.R. China.
  • Fang L; Affiliated Hospital of North Sichuan Medical College, Nanchong, P.R. China.
  • Liu W; Affiliated Hospital of North Sichuan Medical College, Nanchong, P.R. China.
  • Huang Y; Affiliated Hospital of North Sichuan Medical College, Nanchong, P.R. China.
  • Mao W; Affiliated Hospital of North Sichuan Medical College, Nanchong, P.R. China.
  • Chen Y; Institute of Blood Transfusion, Chongqing Blood Center, Chongqing, P.R. China. maoweicqbc@163.com.
  • Zou Q; Chongqing Public Health Medical Central, Chongqing, P.R. China. yaokaichen@hotmail.com.
Signal Transduct Target Ther ; 5(1): 219, 2020 10 06.
Article in English | MEDLINE | ID: covidwho-834865
Semantic information from SemMedBD (by NLM)
1. Evaluation TREATS COVID-19
Subject
Evaluation
Predicate
TREATS
Object
COVID-19
2. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
3. Evaluation TREATS Patients
Subject
Evaluation
Predicate
TREATS
Object
Patients
4. Patients LOCATION_OF Plasma
Subject
Patients
Predicate
LOCATION_OF
Object
Plasma
5. Donor person LOCATION_OF Plasma
Subject
Donor person
Predicate
LOCATION_OF
Object
Plasma
6. Serologic tests MEASURES Immunoglobulin level - finding
Subject
Serologic tests
Predicate
MEASURES
Object
Immunoglobulin level - finding
7. Lung LOCATION_OF Lesion
Subject
Lung
Predicate
LOCATION_OF
Object
Lesion
8. Viremia PROCESS_OF Patients
Subject
Viremia
Predicate
PROCESS_OF
Object
Patients
9. Lesion PROCESS_OF Patients
Subject
Lesion
Predicate
PROCESS_OF
Object
Patients
10. Negative PROCESS_OF Patients
Subject
Negative
Predicate
PROCESS_OF
Object
Patients
11. Borg Category-Ratio 10 Perceived Exertion Score 5 PROCESS_OF Patients
Subject
Borg Category-Ratio 10 Perceived Exertion Score 5
Predicate
PROCESS_OF
Object
Patients
12. Evaluation TREATS COVID-19
Subject
Evaluation
Predicate
TREATS
Object
COVID-19
13. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
14. Evaluation TREATS Patients
Subject
Evaluation
Predicate
TREATS
Object
Patients
15. Patients LOCATION_OF Plasma
Subject
Patients
Predicate
LOCATION_OF
Object
Plasma
16. Donor person LOCATION_OF Plasma
Subject
Donor person
Predicate
LOCATION_OF
Object
Plasma
17. Serologic tests MEASURES Immunoglobulin level - finding
Subject
Serologic tests
Predicate
MEASURES
Object
Immunoglobulin level - finding
18. Lung LOCATION_OF Lesion
Subject
Lung
Predicate
LOCATION_OF
Object
Lesion
19. Viremia PROCESS_OF Patients
Subject
Viremia
Predicate
PROCESS_OF
Object
Patients
20. Lesion PROCESS_OF Patients
Subject
Lesion
Predicate
PROCESS_OF
Object
Patients
21. Negative PROCESS_OF Patients
Subject
Negative
Predicate
PROCESS_OF
Object
Patients
22. Borg Category-Ratio 10 Perceived Exertion Score 5 PROCESS_OF Patients
Subject
Borg Category-Ratio 10 Perceived Exertion Score 5
Predicate
PROCESS_OF
Object
Patients
ABSTRACT
Convalescent plasma (CP) transfusion has been indicated as a promising therapy in the treatment for other emerging viral infections. However, the quality control of CP and individual variation in patients in different studies make it rather difficult to evaluate the efficacy and risk of CP therapy for coronavirus disease 2019 (COVID-19). We aimed to explore the potential efficacy of CP therapy, and to assess the possible factors associated with its efficacy. We enrolled eight critical or severe COVID-19 patients from four centers. Each patient was transfused with 200-400 mL of CP from seven recovered donors. The primary indicators for clinical efficacy assessment were the changes of clinical symptoms, laboratory parameters, and radiological image after CP transfusion. CP donors had a wide range of antibody levels measured by serology tests which were to some degree correlated with the neutralizing antibody (NAb) level. No adverse events were observed during and after CP transfusion. Following CP transfusion, six out of eight patients showed improved oxygen support status; chest CT indicated varying degrees of absorption of pulmonary lesions in six patients within 8 days; the viral load was decreased to a negative level in five patients who had the previous viremia; other laboratory parameters also tended to improve, including increased lymphocyte counts, decreased C-reactive protein, procalcitonin, and indicators for liver function. The clinical efficacy might be associated with CP transfusion time, transfused dose, and the NAb levels of CP. This study indicated that CP might be a potential therapy for severe patients with COVID-19.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Antibodies, Neutralizing / Betacoronavirus / Antibodies, Viral Type of study: Case report / Diagnostic study / Experimental Studies / Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: Signal Transduct Target Ther Year: 2020 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Antibodies, Neutralizing / Betacoronavirus / Antibodies, Viral Type of study: Case report / Diagnostic study / Experimental Studies / Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: Signal Transduct Target Ther Year: 2020 Document Type: Article